Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

600332 Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

Closed 03-25 15:00:00

26.87

+0.18

+0.67%

High26.92	Low26.57	Vol8.46M
Open26.65	D1 Closing26.69	Amplitude1.31%
Mkt Cap43.69B	Tradable Cap37.78B	Total Shares1.63B
T/O227.00M	T/O Rate0.60%	Tradable Shares1.41B
P/B1.22	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"600332","market":"SH","secType":"STK","nameCN":"Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited","latestPrice":26.87,"timestamp":1742886000000,"preClose":26.69,"halted":0,"volume":8458080,"delay":0,"changeRate":0.0067,"floatShares":1406000000,"shares":1626000000,"eps":0.9936,"marketStatus":"Closed","change":0.18,"latestTime":"03-25 15:00:00","open":26.65,"high":26.92,"low":26.57,"amount":227000000,"amplitude":0.0131,"askPrice":26.88,"askSize":993,"bidPrice":26.87,"bidSize":283,"shortable":0,"etf":0,"ttmEps":0.9936,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1742952600000},"marketStatusCode":5,"adr":0,"adjPreClose":26.69,"symbolType":"stock","openAndCloseTimeList":[[1742866200000,1742873400000],[1742878800000,1742886000000]],"highLimit":29.36,"lowLimit":24.02,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1625790949,"isCdr":false,"pbRate":1.22,"roa":"--","peRate":27.043076,"roe":"7.99%","epsLYR":1.744,"committee":-0.491669,"marketValue":43685000000,"turnoverRate":0.006,"status":0,"hkstockBrief":{"symbol":"00874","market":"HK","secType":"STK","nameCN":"BAIYUNSHAN PH","latestPrice":17.3,"timestamp":1742890083013,"preClose":17.4,"halted":0,"volume":998300,"delay":0,"premium":"-39.86"},"floatMarketCap":37776000000},"requestUrl":"/m/hq/s/600332/wiki","defaultTab":"wiki","newsList":[{"id":"2520869664","title":"Baiyunshan Pharmaceutical Gets Nod to Outsource Ginger Granule Production","url":"https://stock-news.laohu8.com/highlight/detail?id=2520869664","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520869664?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 13:23","pubTimestamp":1742275435,"startTime":"0","endTime":"0","summary":"Guangzhou Baiyunshan Pharmaceutical  subsidiary Zhongyi Pharmaceutical received approval from Guangdong Province's drug administrator to update its drug production license.The license permits Zhongyi Pharmaceutical to outsource the production of ginger granules to Baiyunshan Pharmaceutical General Factory, according to a Monday filing with the Shanghai bourse.The outsourcing is valid for three years.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0175","BK0012","BK0028","BK0196","BK0239","BK0097","BK0096","BK0183","BK0188","600332","BK0070"],"gpt_icon":0},{"id":"2519811680","title":"Guangzhou Baiyunshan Pharmaceutical Plans to Apply for Credit Line","url":"https://stock-news.laohu8.com/highlight/detail?id=2519811680","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519811680?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 11:23","pubTimestamp":1741922617,"startTime":"0","endTime":"0","summary":"Guangzhou Baiyunshan Pharmaceutical  is planning to apply for a credit line of up to 54.1 billion yuan and a total of up to HK$100 million from financial institutions.The credit will support daily operations, working capital needs and financing flexibility, according to a Thursday filing with the Shanghai bourse.Shares of the pharmaceutical company were down more than 1% in recent trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","BK0188","BK0070","600332","BK0012","BK0183","BK0175","BK0096","BK0028","BK0097","BK0196"],"gpt_icon":0},{"id":"2519816833","title":"Baiyunshan Pharmaceutical 2024 Profit Down 30%, Revenue Slips 0.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2519816833","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519816833?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 10:38","pubTimestamp":1741919907,"startTime":"0","endTime":"0","summary":"Guangzhou Baiyunshan Pharmaceutical  posted 2024 net profit attributable to shareholders of 2.84 billion yuan, down 30% from 4.06 billion yuan the previous year.Revenue ticked down 0.7% year over year to 75.0 billion yuan from 75.5 billion yuan, according to a Thursday filing with the Shanghai bourse.Shares of the pharmaceutical company were down 2% in recent trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["600332"],"gpt_icon":0},{"id":"2519839259","title":"Baiyunshan Pharmaceutical  Says 2024 Net Profit Down 30.1% Y/Y","url":"https://stock-news.laohu8.com/highlight/detail?id=2519839259","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519839259?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 20:51","pubTimestamp":1741870314,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250313:nL4N3PW10A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0096","BK0028","BK0012","BK0188","BK0070","BK0097","BK0183","BK0239","600332","BK0175","BK0196"],"gpt_icon":0},{"id":"2519483212","title":"BRIEF-Baiyunshan Pharmaceutical's 2024 Net Profit Down 30.1% Y/Y","url":"https://stock-news.laohu8.com/highlight/detail?id=2519483212","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519483212?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 20:51","pubTimestamp":1741870314,"startTime":"0","endTime":"0","summary":"BRIEF-Baiyunshan Pharmaceutical's 2024 Net Profit Down 30.1% Y/YMarch 13 (Reuters) - Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd 600332.SS:SAYS 2024 NET PROFIT DOWN 30.1% Y/YSource textFurther company coverage: 600332.SS (Reporting by Beijing Newsroom) ((Ethan.Wang@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250313:nL4N3PW10A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["600332","BK0196","BK0012","BK0070","BK0188","BK0028","BK0097","BK0096","BK0239","BK0183","BK0175"],"gpt_icon":0},{"id":"2517268781","title":"Baiyunshan Pharmaceutical's Branch Gets Nod to Market Atorvastatin Calcium","url":"https://stock-news.laohu8.com/highlight/detail?id=2517268781","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517268781?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 12:26","pubTimestamp":1741321611,"startTime":"0","endTime":"0","summary":"A branch of Guangzhou Baiyunshan Pharmaceutical (SHA:600332, HKG:0874), Baiyunshan Chemical Pharmaceutical Factory, received the Chinese drug administration's approval to market atorvastatin calcium, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1521","BK0188","BK0070","BK0096","BK1197","BK1515","BK0175","00874","600332","BK0012","BK1191","BK1606","BK0196","BK0097","BK0239","BK0183","BK0028"],"gpt_icon":0},{"id":"2517712365","title":"DIARY-China corporate earnings week ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2517712365","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517712365?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 12:00","pubTimestamp":1741320000,"startTime":"0","endTime":"0","summary":"DIARY-China corporate earnings week aheadMarch 7 (Reuters) - Diary of China (.CSI300) corporate earnings for the week ahead.CHINA EARNINGS Start DateStart Time(GMT)RICCompany NameEvent Name13-Mar-2025","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250307:nL3N3PP18E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["600332","COMM"],"gpt_icon":0},{"id":"2517049669","title":"Baiyunshan Pharma's Unit Gets Regulatory Nod to Amend License","url":"https://stock-news.laohu8.com/highlight/detail?id=2517049669","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517049669?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 12:32","pubTimestamp":1741235563,"startTime":"0","endTime":"0","summary":"Guangzhou Baiyunshan Pharmaceutical's  subsidiary, Guangzhou Baiyunshan Mingxing Pharmaceutical, obtained the Guangdong Provincial Drug Administration's approval to amend its license, according to a Shanghai Stock Exchange disclosure on Wednesday.The changes included amending the production address to Xiahengtian Industrial Zone, Shayong Village, Lishui Town, Nanhai District, Foshan City, China from No. 1, Jiantashan Road, Huangpu District, Guangzhou, China. The scope of the production was also lessened, the pharmaceutical company said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0175","00874","BK0183","BK1191","BK1197","BK0096","BK0188","BK0196","BK1515","BK1606","BK0012","BK0097","BK0028","BK1521","600332","BK0070","BK0239"],"gpt_icon":0},{"id":"2514479312","title":"Guangzhou Baiyunshan Pharmaceutical - Disposal of Second New Underlying Assets of Gp Corp. to Industrial Securities Asset Management for RMB583.1 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2514479312","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514479312?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 16:32","pubTimestamp":1740731521,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nFWN3PI2JL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0239","BK1197","00874","BK0183","BK0012","BK0070","BK1515","BK0097","BK1606","BK0196","BK1521","BK0096","600332","BK0175","BK1191","BK0028","BK0188"],"gpt_icon":0},{"id":"2514353773","title":"MORNING BID ASIA-Tariffs, tech fatigue rev up month-end turbulence","url":"https://stock-news.laohu8.com/highlight/detail?id=2514353773","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514353773?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 05:45","pubTimestamp":1740692700,"startTime":"0","endTime":"0","summary":"MORNING BID ASIA-Tariffs, tech fatigue rev up month-end turbulenceWe're excited to announce that Morning Bid Asia will be rebranded as Trading Day as of March 3. It's not just the title that's changing. We're enhancing the newsletter to offer you more in-depth analysis and insightful commentary on global markets from Jamie McGeever, Reuters' markets columnist. We hope you'll enjoy the new format.By Jamie McGeever","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nL5N3PI2FW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1868836914.USD","2NVD.UK","LU1244550494.USD","NVD3.UK","NVDY","LU0006306889.USD","SNVD.UK","LU0683600562.USD","NVDS","LU2756315318.SGD","LU0345768153.USD","LU0265550359.USD","NVDA","LU1069344957.HKD","SG9999015945.SGD","LU1548497426.USD","LU2294711713.HKD","LU2361044949.HKD","IE0004445239.USD","NVIW.SI","LU1720051108.HKD","600332","BK4574","LU0823421416.USD","LU2065169927.USD","LU1852331112.SGD","NVD","LU0056508442.USD","LU0203201768.USD","NVDX","NVD2.UK","LU0061474705.USD","TSYW.SI","3NVD.UK","NVDS.UK","LU2413666699.HKD","LU1778281490.HKD","BK4581","BK4529","BK0196","LU2491050071.SGD","LU2242649171.HKD","NVDD","LU2125909247.SGD","NVDU","LU0868494708.USD","LU0979878070.USD","LU1037948897.HKD"],"gpt_icon":1},{"id":"2511231691","title":"BRIEF-Guangzhou Baiyunshan Pharmaceutical Received Written Resignation From Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2511231691","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511231691?lang=en_us&edition=full_marsco","pubTime":"2025-02-14 23:18","pubTimestamp":1739546327,"startTime":"0","endTime":"0","summary":"BRIEF-Guangzhou Baiyunshan Pharmaceutical Received Written Resignation From Executive DirectorFeb 14  - Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd 600332.SS:RECEIVED WRITTEN RESIGNATION FROM WU CHANGHAI AS EXECUTIVE DIRECTORFurther company coverage: 600332.SS ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250214:nFWN3P5160:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0183","BK0028","BK0097","BK0239","BK0175","BK0096","BK1197","BK0188","BK0196","BK1515","BK0012","BK0070","00874","600332","BK1521","BK1606","BK1191"],"gpt_icon":0},{"id":"2511668333","title":"Guangzhou Baiyunshan Pharmaceutical - Received Written Resignation From Wu Changhai as Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2511668333","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511668333?lang=en_us&edition=full_marsco","pubTime":"2025-02-14 18:07","pubTimestamp":1739527648,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250214:nFWN3P5160:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0183","BK0196","BK1515","BK0012","BK0028","00874","BK1197","BK0188","BK1521","BK1606","BK0070","BK0239","BK0097","BK0096","BK1191","BK0175","600332"],"gpt_icon":0},{"id":"2511550768","title":"Baiyunshan Pharmaceutical Gets Regulatory Approval to Amend Drug Production License","url":"https://stock-news.laohu8.com/highlight/detail?id=2511550768","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511550768?lang=en_us&edition=full_marsco","pubTime":"2025-02-13 11:14","pubTimestamp":1739416481,"startTime":"0","endTime":"0","summary":"Guangzhou Baiyunshan Pharmaceutical  subsidiary Hejigong Pharmaceutical Factory received approval from Guangdong's drug administrator to amend its drug production license.The amendment involves the reduction of the \"F Building Production Line\" at the Xingzhou manufacturing department located at 4 South Chuangye Ave., Mingzhu Industrial Park in Guangzhou, according to a Wednesday filing with the Shanghai bourse.The F Building Production Line was primarily used for the pre-processing and extraction of traditional Chinese medicine. The adjustment is part of the company's efforts to optimize resource allocation and maintain stable production capacity to meet market demands.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0096","BK0028","BK0012","BK0188","BK0070","BK0097","BK0183","BK0239","600332","BK0175","BK0196"],"gpt_icon":0},{"id":"2505331948","title":"Guangzhou Baiyunshan Pharmaceutical Passes Generic Drug Evaluation for Antibiotic Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2505331948","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505331948?lang=en_us&edition=full_marsco","pubTime":"2025-01-24 16:56","pubTimestamp":1737709012,"startTime":"0","endTime":"0","summary":"Guangzhou Baiyunshan Pharmaceutical  said its factory passed the generic drug quality and efficacy consistency evaluation for amoxicillin clavulanate potassium dry suspension.The drug is a penicillin antibiotic used to treat various infections, according to a Thursday filing with the Shanghai bourse.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["600332","BK0070","BK0097","BK0188","BK0175","BK0012","BK0196","BK0183","BK0239","BK0096","BK0028"],"gpt_icon":0},{"id":"2505270340","title":"BRIEF-Guangzhou Baiyunshan Pharmaceutical Says Liu Juyan Resigns As Executive Director Of 9th Session","url":"https://stock-news.laohu8.com/highlight/detail?id=2505270340","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505270340?lang=en_us&edition=full_marsco","pubTime":"2025-01-21 23:37","pubTimestamp":1737473871,"startTime":"0","endTime":"0","summary":"BRIEF-Guangzhou Baiyunshan Pharmaceutical Says Liu Juyan Resigns As Executive Director Of 9th SessionJan 21  - Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd 600332.SS:RECEIVED RESIGNATION FROM LIU JUYAN AS EXECUTIVE DIRECTOR OF 9TH SESSIONFurther company coverage: 600332.SS ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250121:nFWN3OH0NA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1197","BK0070","BK1515","BK1521","00874","BK0096","600332","BK0097","BK0175","BK0183","BK0196","BK0188","BK1606","BK0239","BK1191","BK0012","BK0028"],"gpt_icon":0},{"id":"2505474472","title":"Guangzhou Baiyunshan Pharmaceutical -  Received Resignation From Liu Juyan as Executive Director of 9TH Session","url":"https://stock-news.laohu8.com/highlight/detail?id=2505474472","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505474472?lang=en_us&edition=full_marsco","pubTime":"2025-01-21 18:44","pubTimestamp":1737456289,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250121:nFWN3OH0NA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1515","00874","BK0028","BK0239","BK1191","BK0096","BK0175","BK0012","BK1606","BK1521","BK1197","BK0196","BK0188","BK0070","BK0183","600332","BK0097"],"gpt_icon":0},{"id":"2505420212","title":"BRIEF-Guangzhou Baiyunshan Pharmaceutical Elects Chairman","url":"https://stock-news.laohu8.com/highlight/detail?id=2505420212","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505420212?lang=en_us&edition=full_marsco","pubTime":"2025-01-21 18:29","pubTimestamp":1737455377,"startTime":"0","endTime":"0","summary":"BRIEF-Guangzhou Baiyunshan Pharmaceutical Elects ChairmanJan 21  - Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd 600332.SS:SAYS BOARD AGREES TO ELECT LI XIAOJUN AS CHAIRMANSource textFurther company coverage: 600332.SS  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250121:nL3N3OH0TK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0183","BK0188","BK0175","BK0097","BK0028","BK0070","BK0239","BK0012","600332","BK0096","BK0196"],"gpt_icon":0},{"id":"2505230242","title":"Guangzhou Baiyunshan Pharmaceutical  Says Board Agrees to Elect Li Xiaojun as Chairman","url":"https://stock-news.laohu8.com/highlight/detail?id=2505230242","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505230242?lang=en_us&edition=full_marsco","pubTime":"2025-01-21 18:29","pubTimestamp":1737455377,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250121:nL3N3OH0TK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0183","BK0097","BK0028","BK0196","BK0188","BK0239","BK0096","BK0175","600332","BK0012","BK0070"],"gpt_icon":0},{"id":"2503938778","title":"Guangzhou Baiyunshan Pharma Gets Local Approval to Reduce, Add Production Lines","url":"https://stock-news.laohu8.com/highlight/detail?id=2503938778","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503938778?lang=en_us&edition=full_marsco","pubTime":"2025-01-16 12:08","pubTimestamp":1737000535,"startTime":"0","endTime":"0","summary":"Authorities in Guangdong, China approved Guangzhou Baiyunshan Pharmaceutical's  reduction and addition of drug production lines, according to a Thursday filing with the Shanghai Stock Exchange.The changes include reducing the Building F production line in Guangzhou, China, where it produces its Huatuo Zaizao, Yifu Zhixue, and Jindan traditional Chinese pills, and adding the Building D production line for its Qingre Sanjie traditional Chinese tablets, the filing said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","BK0188","BK0070","600332","BK0012","BK0183","BK0175","BK0096","BK0028","BK0097","BK0196"],"gpt_icon":0},{"id":"2501795426","title":"Baiyunshan Pharma's Venture Capital Fund Completes Registration","url":"https://stock-news.laohu8.com/highlight/detail?id=2501795426","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501795426?lang=en_us&edition=full_marsco","pubTime":"2025-01-08 11:58","pubTimestamp":1736308724,"startTime":"0","endTime":"0","summary":"Guangzhou Baiyunshan Pharmaceutical  said the 400 million yuan venture capital fund it invested in completed its industrial and commercial registration, according to a Shanghai Stock Exchange disclosure on Tuesday.The fund, Guangzhou Guangyao Industrial Investment Venture Capital Fund Partnership , completed the filing procedures with the Asset Management Association of China, the pharmaceutical company said.Baiyunshan Pharma's Shanghai shares slipped more than 1% and Hong Kong shares fell less than 2% in recent trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","BK0188","BK0070","600332","BK1191","00874","BK1606","BK0012","BK1515","BK0183","BK0175","BK1521","BK0096","BK1197","BK0028","BK0097","BK0196"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2001-02-06","address":"广东省广州市荔湾区沙面北街45号","stockEarnings":[{"period":"1week","weight":-0.0048},{"period":"1month","weight":-0.0022},{"period":"3month","weight":-0.0765},{"period":"6month","weight":0.0366},{"period":"1year","weight":-0.039},{"period":"ytd","weight":-0.0609}],"companyName":"广州白云山医药集团股份有限公司","boardCode":"AI0027","perCapita":"15740股","boardName":"医药制造业","registeredCapital":"162579万元","compareEarnings":[{"period":"1week","weight":-0.0164},{"period":"1month","weight":-0.0027},{"period":"3month","weight":-0.0069},{"period":"6month","weight":0.1636},{"period":"1year","weight":0.1056},{"period":"ytd","weight":0.0054}],"survey":"　　广州白云山医药集团股份有限公司的主营业务是中西成药、化学原料药、天然药物、生物医药、化学原料药中间体的研发、制造与销售；西药、中药和医疗器械的批发、零售和进出口业务；大健康产品的研发、生产与销售；医疗服务、健康管理、养生养老等健康产业投资。公司的主要产品是中成药、化学药。本集团及合营企业共获得国家科技进步奖1项，省级科技进步奖3项，其中白云山和黄公司“中药质量检测技术集成创新与支撑体系创建及应用”荣获“国家科学技术进步奖”。","serverTime":1742902970445,"listedPrice":9.8,"stockholders":"89316人(较上一季度增加5.88%)","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited,600332,Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited股票,Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited股票老虎,Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited股票老虎国际,Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited行情,Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited股票行情,Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited股价,Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited股市,Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited股票价格,Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited股票交易,Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited股票购买,Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction